PURPOSE: To enhance the systemic exposure to oral docetaxel by coadministration of ritonavir, an efficacious inhibitor of CYP 3A4 with minor P-glycoprotein inhibiting effects, in patients with cancer. EXPERIMENTAL DESIGN: A proof-of-concept study was carried out in 12 patients with solid tumors. The first cohort of patients (n = 4) received 10 mg and the subsequent cohort (n = 8) 100 mg of oral docetaxel, coadministered with 100 mg oral ritonavir randomized simultaneously or ritonavir given 60 minutes before docetaxel on days 1 and 8. On day 15 or 22, patients received 100 mg i.v. docetaxel. RESULTS: The area under the plasma concentration-time curve in patients who received 10 mg oral docetaxel in combination with ritonavir was low, and the dose could safely be increased to 100 mg. The area under the plasma concentration-time curve in patients who received 100 mg oral docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 2.4 +/- 1.5 and 2.8 +/- 1.4 mg/h/L, respectively, compared with 1.9 +/- 0.4 mg/h/L after i.v. docetaxel. The apparent oral bioavailability of docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 131% +/- 90% and 161% +/- 91%, respectively. The oral combination of docetaxel and ritonavir was well tolerated. CONCLUSION: Coadministration of ritonavir significantly enhanced the apparent oral bioavailability of docetaxel. These data are promising and form the basis for further development of a clinically applicable oral formulation of docetaxel combined with ritonavir.
RCT Entities:
PURPOSE: To enhance the systemic exposure to oral docetaxel by coadministration of ritonavir, an efficacious inhibitor of CYP 3A4 with minor P-glycoprotein inhibiting effects, in patients with cancer. EXPERIMENTAL DESIGN: A proof-of-concept study was carried out in 12 patients with solid tumors. The first cohort of patients (n = 4) received 10 mg and the subsequent cohort (n = 8) 100 mg of oral docetaxel, coadministered with 100 mg oral ritonavir randomized simultaneously or ritonavir given 60 minutes before docetaxel on days 1 and 8. On day 15 or 22, patients received 100 mg i.v. docetaxel. RESULTS: The area under the plasma concentration-time curve in patients who received 10 mg oral docetaxel in combination with ritonavir was low, and the dose could safely be increased to 100 mg. The area under the plasma concentration-time curve in patients who received 100 mg oral docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 2.4 +/- 1.5 and 2.8 +/- 1.4 mg/h/L, respectively, compared with 1.9 +/- 0.4 mg/h/L after i.v. docetaxel. The apparent oral bioavailability of docetaxel combined with ritonavir simultaneously or ritonavir given 60 minutes before docetaxel was 131% +/- 90% and 161% +/- 91%, respectively. The oral combination of docetaxel and ritonavir was well tolerated. CONCLUSION: Coadministration of ritonavir significantly enhanced the apparent oral bioavailability of docetaxel. These data are promising and form the basis for further development of a clinically applicable oral formulation of docetaxel combined with ritonavir.
Authors: Johannes J Moes; Frederik E Stuurman; Jeroen J M A Hendrikx; Serena Marchetti; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens; Bastiaan Nuijen Journal: Drug Deliv Transl Res Date: 2013-06 Impact factor: 4.617
Authors: Huixin Yu; Julie M Janssen; Vincent A de Weger; Bastiaan Nuijen; Rik E Stuurman; Serena Marchetti; Jan H M Schellens; Jos H Beijnen; Thomas P C Dorlo; Alwin D R Huitema Journal: Invest New Drugs Date: 2020-04-19 Impact factor: 3.850
Authors: Stijn L W Koolen; Roos L Oostendorp; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2010-05 Impact factor: 4.335
Authors: Marit A C Vermunt; Lisa T van der Heijden; Jeroen J M A Hendrikx; Alfred H Schinkel; Vincent A de Weger; Eric van der Putten; Baukelien van Triest; Andries M Bergman; Jos H Beijnen Journal: Cancer Chemother Pharmacol Date: 2021-03-20 Impact factor: 3.333
Authors: Michelle A Rudek; Cathy Y Chang; Kenneth Steadman; Michael D Johnson; Naveen Desai; John F Deeken Journal: Cancer Chemother Pharmacol Date: 2014-02-02 Impact factor: 3.333